Vertex Pharma stock: BofA cuts target for Vertex Pharma stock from USD 672.00 to USD 667.00

Published on 10/19/2026 at 16:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 12.50 percent to USD 3.33 billion. Vertex Pharma stock costs EUR 447.93 on October 19, 2026 at 4:36 p.m. CEST.

Analyst and calendar markers

On October 12, 2026, BofA Securities lowered its Vertex target from USD 672.00 to USD 667.00.
Second-quarter revenue rose 12.50 percent to USD 3.33 billion.
Vertex Pharma stock costs EUR 447.93 at Lang & Schwarz on October 19, 2026 at 4:36 p.m. CEST.
Vertex Pharmaceuticals will report third-quarter 2026 results on November 2, 2026.

Bauhaus-Poster mit geometrischen Formen, Molekülsymbol und großem Schriftzug PHARMA — Vertex Pharma US92532F1003 zeigt ein geometrisches Bauhaus-Poster mit Sektor-Text PHARMA und stilisierter Molekülgrafik, Illustration mit AI erstellt.

BofA Securities lowered its price target for Vertex Pharmaceuticals from USD 672.00 to USD 667.00 on October 12, 2026, while keeping its Buy rating, as Investing.com reported. Against the Nasdaq quote of USD 501.04 on October 19, 2026, the new target is 33.12 percent higher. Vertex Pharma was trading at EUR 447.93 at Lang & Schwarz on October 19, 2026 at 4:36 p.m. CEST.

Second-quarter revenue rose 12.50 percent

Vertex Pharmaceuticals reported USD 3.33 billion in revenue for the second quarter of 2026, up 12.50 percent from USD 2.96 billion a year earlier. Net income reached USD 1.10 billion, compared with USD 1.03 billion in the second quarter of 2025, according to Ticker Scout.

The product mix is shifting inside cystic fibrosis. ALYFTREK revenue reached USD 573.6 million in the second quarter of 2026, up 265.8 percent year over year, while TRIKAFTA and KAFTRIO revenue fell 2.10 percent to USD 2.50 billion in the same period, the filing summary said.

Price position and valuation

The Nasdaq quote stood at USD 501.04 at 10:43 a.m. ET on October 19, 2026, up 0.26 percent from the previous Nasdaq close. The same quote was 10.57 percent below the USD 560.25 52-week high and 24.27 percent above the USD 403.16 low. Market capitalization was USD 127.0 billion and the trailing price-to-earnings ratio was 29.24.

BofA's USD 667.00 target gives the stock a dated analyst reference above the Nasdaq price. The next scheduled corporate date is November 2, 2026, when Vertex will report third-quarter 2026 results after the market close, according to Vertex Pharmaceuticals.

Comparison with peers

Vertex Pharma (Nasdaq, USD): plus 0.26 percent, P/E 29.24, market capitalization USD 127.0 billion
Gilead Sciences (Nasdaq, USD): minus 0.45 percent, P/E minus 58.41, market capitalization USD 192.8 billion
Moderna (Nasdaq, USD): plus 2.07 percent, P/E minus 28.11, market capitalization USD 88.8 billion

Trading details for investors

Vertex Pharma's euro quote is the relevant German-market indication for this report, while the Nasdaq figures place the company in its home-market currency. The valuation contrast with Gilead and Moderna reflects different earnings bases and does not provide a ranking.

The stock had been supported by a broad analyst target range, but the October 12 BofA reduction puts the USD 667.00 target below its earlier level. The second-quarter revenue increase remains the latest reported operating comparison, with the newer ALYFTREK product growing faster than the established TRIKAFTA and KAFTRIO franchise.

Vertex Pharma was trading at EUR 447.93 at Lang & Schwarz on October 19, 2026 at 4:36 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.